Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

In vivo performance of polymer nanocarriers dually-targeted to epitopes of the same or different receptors.

Papademetriou IT, Garnacho C, Schuchman EH, Muro S.

Biomaterials. 2013 Apr;34(13):3459-66. doi: 10.1016/j.biomaterials.2013.01.069. Epub 2013 Feb 9.

2.

Comparative binding, endocytosis, and biodistribution of antibodies and antibody-coated carriers for targeted delivery of lysosomal enzymes to ICAM-1 versus transferrin receptor.

Papademetriou J, Garnacho C, Serrano D, Bhowmick T, Schuchman EH, Muro S.

J Inherit Metab Dis. 2013 May;36(3):467-77. doi: 10.1007/s10545-012-9534-6. Epub 2012 Sep 12.

3.

Combination-targeting to multiple endothelial cell adhesion molecules modulates binding, endocytosis, and in vivo biodistribution of drug nanocarriers and their therapeutic cargoes.

Papademetriou I, Tsinas Z, Hsu J, Muro S.

J Control Release. 2014 Aug 28;188:87-98. doi: 10.1016/j.jconrel.2014.06.008. Epub 2014 Jun 14.

4.
5.

Enhanced delivery of α-glucosidase for Pompe disease by ICAM-1-targeted nanocarriers: comparative performance of a strategy for three distinct lysosomal storage disorders.

Hsu J, Northrup L, Bhowmick T, Muro S.

Nanomedicine. 2012 Jul;8(5):731-9. doi: 10.1016/j.nano.2011.08.014. Epub 2011 Sep 9.

6.

Delivery of acid sphingomyelinase in normal and niemann-pick disease mice using intercellular adhesion molecule-1-targeted polymer nanocarriers.

Garnacho C, Dhami R, Simone E, Dziubla T, Leferovich J, Schuchman EH, Muzykantov V, Muro S.

J Pharmacol Exp Ther. 2008 May;325(2):400-8. doi: 10.1124/jpet.107.133298. Epub 2008 Feb 20.

7.

Lysosomal enzyme delivery by ICAM-1-targeted nanocarriers bypassing glycosylation- and clathrin-dependent endocytosis.

Muro S, Schuchman EH, Muzykantov VR.

Mol Ther. 2006 Jan;13(1):135-41. Epub 2005 Sep 8.

PMID:
16153895
8.

Biodistribution and endocytosis of ICAM-1-targeting antibodies versus nanocarriers in the gastrointestinal tract in mice.

Mane V, Muro S.

Int J Nanomedicine. 2012;7:4223-37. doi: 10.2147/IJN.S34105. Epub 2012 Aug 1.

9.

Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.

Muro S, Dziubla T, Qiu W, Leferovich J, Cui X, Berk E, Muzykantov VR.

J Pharmacol Exp Ther. 2006 Jun;317(3):1161-9. Epub 2006 Feb 27.

10.

Clathrin-mediated endocytosis is impaired in type A-B Niemann-Pick disease model cells and can be restored by ICAM-1-mediated enzyme replacement.

Rappaport J, Garnacho C, Muro S.

Mol Pharm. 2014 Aug 4;11(8):2887-95. doi: 10.1021/mp500241y. Epub 2014 Jun 26.

11.
12.

In vivo imaging of 64Cu-labeled polymer nanoparticles targeted to the lung endothelium.

Rossin R, Muro S, Welch MJ, Muzykantov VR, Schuster DP.

J Nucl Med. 2008 Jan;49(1):103-11. Epub 2007 Dec 12.

13.

Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting.

Ansar M, Serrano D, Papademetriou I, Bhowmick TK, Muro S.

ACS Nano. 2013 Dec 23;7(12):10597-611. doi: 10.1021/nn404719c. Epub 2013 Nov 20.

14.

Targeting, endocytosis, and lysosomal delivery of active enzymes to model human neurons by ICAM-1-targeted nanocarriers.

Hsu J, Hoenicka J, Muro S.

Pharm Res. 2015 Apr;32(4):1264-78. doi: 10.1007/s11095-014-1531-z. Epub 2014 Oct 16.

PMID:
25319100
15.

Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1.

Bhowmick T, Berk E, Cui X, Muzykantov VR, Muro S.

J Control Release. 2012 Feb 10;157(3):485-92. doi: 10.1016/j.jconrel.2011.09.067. Epub 2011 Sep 16.

16.

Enhanced endothelial delivery and biochemical effects of α-galactosidase by ICAM-1-targeted nanocarriers for Fabry disease.

Hsu J, Serrano D, Bhowmick T, Kumar K, Shen Y, Kuo YC, Garnacho C, Muro S.

J Control Release. 2011 Feb 10;149(3):323-31. doi: 10.1016/j.jconrel.2010.10.031. Epub 2010 Nov 1.

17.

Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers.

Muro S, Garnacho C, Champion JA, Leferovich J, Gajewski C, Schuchman EH, Mitragotri S, Muzykantov VR.

Mol Ther. 2008 Aug;16(8):1450-8. doi: 10.1038/mt.2008.127. Epub 2008 Jun 17.

18.

In vivo biodistribution of prion- and GM1-targeted polymersomes following intravenous administration in mice.

Stojanov K, Georgieva JV, Brinkhuis RP, van Hest JC, Rutjes FP, Dierckx RA, de Vries EF, Zuhorn IS.

Mol Pharm. 2012 Jun 4;9(6):1620-7. doi: 10.1021/mp200621v. Epub 2012 May 7.

PMID:
22536790
19.

Specific binding, uptake, and transport of ICAM-1-targeted nanocarriers across endothelial and subendothelial cell components of the blood-brain barrier.

Hsu J, Rappaport J, Muro S.

Pharm Res. 2014 Jul;31(7):1855-66. doi: 10.1007/s11095-013-1289-8. Epub 2014 Feb 21.

20.

Optimizing endothelial targeting by modulating the antibody density and particle concentration of anti-ICAM coated carriers.

Calderon AJ, Bhowmick T, Leferovich J, Burman B, Pichette B, Muzykantov V, Eckmann DM, Muro S.

J Control Release. 2011 Feb 28;150(1):37-44. doi: 10.1016/j.jconrel.2010.10.025. Epub 2010 Nov 1.

Items per page

Supplemental Content

Write to the Help Desk